US FDA issues complete response letter rejecting license extension of empagliflozin for type 1 diabetes

The application had been made on the basis of the phase III EASE trial, but the FDA concluded that that the benefits of empagliflozin 2.5mg did not outweigh the risks as an adjunct to insulin for type 1 diabetes, and requested further larger studies.


Biospace Inc.